AWMSG makes prostate cancer drug abiraterone available on the NHS Cancer Study UK welcomes the news that the All Wales Medicines Strategy Group offers made prostate cancer drug abiraterone on the NHS, paving just how for NICE to create a positive ruling when they publish their final guidance in May. Earlier this complete month after an initial review, NICE announced the medication – developed by Cancer Research UK and others – would not be routinely offered on the NHS because the producer, Janssen, had arranged the price too high More information here . NICE also said the drug did not meet the End of Lifestyle criteria, which could have meant less stringent rules over price applied.
‘The efficacy and tolerability demonstrated by these Stage 2 data further highlight the part that tivozanib may play in the treatment of patients with kidney cancer and other critical cancers, as a single agent or in combination with various other therapies. I am very happy to be taking part in the Stage 3 TIVO-1 trial, and appearance forward to learning more concerning this much-needed potential treatment option as those data become obtainable.’ These data were provided today by Dmitry A. Nosov, M.D., Ph.D., senior medical researcher at the Blokhin Oncology Analysis Center, Moscow, Russian Federation, within an oral presentation titled, ‘Phase 2 Randomized Discontinuation Trial of Tivozanib in Sufferers With Renal Cell Carcinoma : Results in Patients Randomized to Tivozanib vs.